All manuscripts
Publications CAR T Cells γδ T

Generation and proof- of- concept for allogeneic CD123 CAR- Delta One T (DOT) cells in acute myeloid leukemia

Published Journal Journal for ImmunoTherapy of Cancer

Share
No image preview

Overview

The study generates and validates allogeneic CD123 CAR-Delta One T (DOT) cells for AML. These cells showed potent cytotoxicity against AML lines and primary samples. DOT cells were generated from alpha-beta depleted PBMCs cultured in either 96-well plates or the G-Rex® platform.

What this paper found

Retrovirally transduced CD123-directed CAR Delta One T (DOT) cells eliminated CD123+ acute myeloid leukemia blasts far more potently than mock-transduced DOT cells, both in vitro and in patient-derived xenografts. Vδ1-enriched γδ T cells were generated from αβ-depleted healthy-donor mononuclear cells cultured 16-20 days in 96-well plates or the G-Rex® platform and transduced at day 7, keeping ~97% γδ TCR+ and ~70% Vδ1+ purity. Against the MOLM13 and THP-1 lines, CAR-DOTs achieved 20-60% more lysis than mock-DOTs even at 1:16 to 1:4 effector:target ratios, and released more TNF-α, IFN-γ and IL-13. In NSG mice carrying 2.5x10^5 AML-PDX cells, three weekly infusions of 10x10^6 CAR-DOTs controlled leukemia, and daily IL-15 allowed a single dose to control disease beyond 70 days, including after rechallenge.

Note: Preclinical work in cell lines, primary AML samples and mouse xenografts; the authors state that only the clinical setting can establish the real benefit of IL-15 co-administration with DOTs or CD123CAR-DOTs.

These results firmly demonstrate a vigorous and persistent anti-leukemia effect of CD123CAR-DOTs plus daily IL-15, sustained over 70 days and even on tumor rechallenge, thus providing seminal proof-of-concept for their application for adoptive cellular immunotherapy in AML. — Diego Sánchez Martínez, Néstor Tirado, Sofia Mensurado, Alba Martínez-Moreno, Paola Romecín, Francisco Gutiérrez Agüera, Daniel V Correia, Bruno Silva-Santos, Pablo Menéndez, Journal for ImmunoTherapy of Cancer

Study details

Authors
Diego Sánchez Martínez, Néstor Tirado, Sofia Mensurado, Alba Martínez-Moreno, Paola Romecín, Francisco Gutiérrez Agüera, Daniel V Correia, Bruno Silva-Santos, Pablo Menéndez
Institution
Josep Carreras Leukaemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain · Red Española de Terapias Avanzadas (TERAV) - Instituto de Salud Carlos III (ISCII) · Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal · Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Instituto de Salud Carlos III, Barcelona, Spain · Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
Journal
Journal for ImmunoTherapy of Cancer
Year
2022
PMID / PMC
PMID: 36162920 · PMC
Cell type(s)
CAR T Cells, γδ T
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

Alpha-beta-depleted peripheral blood mononuclear cells from healthy-donor buffy coats were cultured in either 96-well plates or the G-Rex® platform (Wilson Wolf Manufacturing) to generate Delta One T cells. The cells were kept in OpTmizer-CTS medium with 2.5% heat-inactivated human plasma, L-glutamine and penicillin/streptomycin for 16-20 days, with anti-CD3 and cytokines added at days 0, 7 and 11. Retroviral transduction with the CD123 CAR was carried out after 7 days of expansion. At the end of culture the cells were harvested and used fresh for in vitro assays or cryopreserved for the in vivo experiments.

Explore related

Full citation

Sánchez Martínez D, Tirado N, Mensurado S, et al. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. J Immunother Cancer. 2022;10(9):e005400.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →